ERS Genomics has completed licensing agreement with Syngene International, following which Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners. 

Syngene International, an integrated research, development and manufacturing services company, is poised to leverage the immense potential of CRISPR/Cas9 in various scientific disciplines, including drug discovery, biotechnology, and genomics on behalf of its clients. 

ERS Genomics, co-founded by Dr Emmanuelle Charpentier, a recipient of the 2020 Nobel Prize in Chemistry for her pioneering work on CRISPR/Cas9, provides access to the definitive patent portfolio for this groundbreaking technology.

The collaboration between ERS Genomics and Syngene marks a significant addition to India's scientific and commercial landscape and reinforces the nation's growing influence in the global biotechnology and life sciences sector. Both organisations are focused on driving scientific progress and bringing transformative innovations to the forefront of research and development.

Mahesh Bhalgat, Chief Operating Officer, Syngene International, said, "This partnership aligns perfectly with our mission to partner with clients to accelerate scientific discovery and support the development of life-changing therapies."